Catherine Stedman

9.2k total citations · 1 hit paper
54 papers, 2.7k citations indexed

About

Catherine Stedman is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Catherine Stedman has authored 54 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Hepatology, 31 papers in Epidemiology and 12 papers in Rheumatology. Recurrent topics in Catherine Stedman's work include Hepatitis C virus research (35 papers), Liver Disease Diagnosis and Treatment (28 papers) and Hepatitis B Virus Studies (12 papers). Catherine Stedman is often cited by papers focused on Hepatitis C virus research (35 papers), Liver Disease Diagnosis and Treatment (28 papers) and Hepatitis B Virus Studies (12 papers). Catherine Stedman collaborates with scholars based in New Zealand, United States and Australia. Catherine Stedman's co-authors include Edward Gane, Murray L. Barclay, Robert H. Hyland, Evguenia S. Svarovskaia, Jing Hieng Ngu, William T. Symonds, Richard B. Gearry, Xiao Ding, M. Michelle Berrey and R. Hindes and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Annals of Internal Medicine.

In The Last Decade

Catherine Stedman

54 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

2013 542 citations Edward Gane, Catherine Stedman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Catherine Stedman New Zealand	26	2.0k	1.8k	398	379	215	54	2.7k
Deepak Amarapurkar India	32	2.3k 1.2×	2.8k 1.5×	1.0k 2.6×	460 1.2×	285 1.3×	115	4.0k
Tobias Goeser Germany	26	2.3k 1.1×	2.6k 1.4×	596 1.5×	456 1.2×	113 0.5×	141	4.1k
Daniel S. Pratt United States	22	1.3k 0.6×	1.3k 0.7×	915 2.3×	371 1.0×	167 0.8×	55	2.8k
Humberto Aguilar United States	14	1.3k 0.6×	1.3k 0.7×	198 0.5×	476 1.3×	89 0.4×	25	2.0k
Harald Hofer Austria	32	3.0k 1.5×	2.7k 1.5×	537 1.3×	247 0.7×	280 1.3×	73	4.0k
E B Keeffe United States	23	2.1k 1.0×	1.9k 1.1×	612 1.5×	212 0.6×	72 0.3×	63	3.0k
G. Idéo Italy	29	3.6k 1.8×	3.3k 1.8×	531 1.3×	270 0.7×	164 0.8×	99	4.4k
Kimberly L. Beavers United States	15	1.9k 0.9×	1.6k 0.9×	919 2.3×	155 0.4×	181 0.8×	26	2.5k
Raymond A. Rubin United States	19	1.5k 0.7×	1.4k 0.7×	437 1.1×	266 0.7×	115 0.5×	44	2.0k
Imam Waked Egypt	29	2.4k 1.2×	2.3k 1.3×	267 0.7×	226 0.6×	71 0.3×	134	3.5k

Countries citing papers authored by Catherine Stedman

Since Specialization

Citations

This map shows the geographic impact of Catherine Stedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Stedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Stedman more than expected).

Fields of papers citing papers by Catherine Stedman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Stedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Stedman. The network helps show where Catherine Stedman may publish in the future.

Co-authorship network of co-authors of Catherine Stedman

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Stedman. A scholar is included among the top collaborators of Catherine Stedman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Stedman. Catherine Stedman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Martinello, Marianne, Sanjay Bhagani, David Shaw, et al.. (2023). Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study. JHEP Reports. 5(10). 100867–100867. 4 indexed citations

Ngu, Jing Hieng, et al.. (2020). Trends in Incidence of Autoimmune Liver Diseases and Increasing Incidence of Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology. 19(3). 573–579.e1. 50 indexed citations

Wade, Amanda, Joseph Doyle, Edward Gane, et al.. (2018). Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial. Trials. 19(1). 383–383. 6 indexed citations

Gane, Edward, Robert H. Hyland, Yin Yang, et al.. (2017). Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection. Gastroenterology. 152(6). 1366–1371. 31 indexed citations

Gane, Edward, Christian Schwabe, Robert H. Hyland, et al.. (2016). Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections. Gastroenterology. 151(3). 448–456.e1. 50 indexed citations

Gane, Edward, Robert H. Hyland, Di An, et al.. (2015). Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection. Gastroenterology. 149(6). 1454–1461.e1. 139 indexed citations

Ngu, Jing Hieng, et al.. (2013). Association of the HLA locus and TNF with type I autoimmune hepatitis susceptibility in New Zealand Caucasians. SpringerPlus. 2(1). 355–355. 13 indexed citations

Gane, Edward, Catherine Stedman, Robert H. Hyland, et al.. (2013). Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection. Gastroenterology. 146(3). 736–743.e1. 157 indexed citations

Ngu, Jing Hieng, Richard B. Gearry, Chris Frampton, & Catherine Stedman. (2013). Autoimmune hepatitis: the role of environmental risk factors: a population-based study. Hepatology International. 7(3). 869–875. 30 indexed citations

10.

Ngu, Jing Hieng, Richard B. Gearry, Chris Frampton, & Catherine Stedman. (2013). Predictors of poor outcome in patients w ith autoimmune hepatitis: A population-based study. Hepatology. 57(6). 2399–2406. 78 indexed citations

11.

Nishimura, Toshihiko, Manhong Wu, Edward A. Pham, et al.. (2012). Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction. Journal of Pharmacology and Experimental Therapeutics. 344(2). 388–396. 49 indexed citations

12.

Chu, Tom, Rohit Kulkarni, Edward Gane, et al.. (2012). Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C. Gastroenterology. 142(4). 790–795. 72 indexed citations

13.

Ngu, Jing Hieng, et al.. (2011). Inflammatory Bowel Disease Is Associated With Poor Outcomes of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology. 9(12). 1092–1097. 73 indexed citations

14.

Ngu, Jing Hieng, et al.. (2011). Low incidence and prevalence of primary biliary cirrhosis in Canterbury, New Zealand: a population-based study. Hepatology International. 6(4). 796–800. 15 indexed citations

15.

Ngu, Jing Hieng, Richard B. Gearry, Chris Frampton, & Catherine Stedman. (2011). Mortality and the Risk of Malignancy in Autoimmune Liver Diseases: A Population-Based Study in Canterbury, New Zealand. Hepatology. 55(2). 522–529. 75 indexed citations

16.

Ngu, Jing Hieng, B. A. Chapman, Michael J. Burt, et al.. (2010). Population‐based epidemiology study of autoimmune hepatitis: A disease of older women?. Journal of Gastroenterology and Hepatology. 25(10). 1681–1686. 136 indexed citations

17.

Gardiner, Sharon J., Richard B. Gearry, Michael J. Burt, et al.. (2010). Allopurinol might improve response to azathioprine and 6‐mercaptopurine by correcting an unfavorable metabolite ratio. Journal of Gastroenterology and Hepatology. 26(1). 49–54. 30 indexed citations

18.

Stedman, Catherine, Christopher Liddle, Sally Coulter, et al.. (2006). Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proceedings of the National Academy of Sciences. 103(30). 11323–11328. 148 indexed citations

19.

Stedman, Catherine, Evan J. Begg, Martin A. Kennedy, Rebecca L Roberts, & Tim Wilkinson. (2002). Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Human Psychopharmacology Clinical and Experimental. 17(4). 187–190. 23 indexed citations

20.

Stedman, Catherine. (2002). Herbal Hepatotoxicity. Seminars in Liver Disease. 22(2). 195–206. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact